S1418/BR006: Testing Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple-Negative Breast Cancer (H-42481)
Description
Content
The purpose of this study is to compare the usual approach (no more treatment, additional chemotherapy and radiation after surgery, or radiation alone after surgery) with any effects of receiving 1 year of treatment with pembrolizumab after surgery. This study will allow researchers to know whether treatment with pembrolizumab is better, the same or worse than the usual approach.
Contact
Phone 1: 713–798–1975
IRB: H-42481
Status:
Active
Created:
